<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="162985">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01721096</url>
  </required_header>
  <id_info>
    <org_study_id>12-398</org_study_id>
    <nct_id>NCT01721096</nct_id>
  </id_info>
  <brief_title>XIENCE PRIME Everolimus Eluting Coronary Stent Post Marketing Surveillance (PMS) in Japan</brief_title>
  <official_title>XIENCE PRIME JAPAN PMS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the PMS are to observe the frequency, type, and degree of device
      deficiency to assure the safety of the new medical device (XIENCE Prime) as well as to
      collect information on evaluation of the efficacy and safety for reevaluation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Stent thrombosis (ST)</measure>
    <time_frame>8 months post index procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Definite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) Definition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stent thrombosis (ST)</measure>
    <time_frame>1 year post index procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Definite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) Definition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stent thrombosis (ST)</measure>
    <time_frame>2 years post index procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Definite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) Definition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stent thrombosis (ST)</measure>
    <time_frame>3 years post index procedrue</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Definite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) Definition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stent thrombosis (ST)</measure>
    <time_frame>4 years post index procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Definite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) Definition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stent thrombosis (ST)</measure>
    <time_frame>5 years post index procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Definite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) Definition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AE) caused by Anti-platelet Medications</measure>
    <time_frame>8 months post index procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>AE caused by Antiplatelet medications include but not limited to
Hepatic disorder
Granulocytopenia
Thrombotic Thrombocytopenic Purpura</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AE) caused by Anti-platelet Medications</measure>
    <time_frame>1 year post index procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>AE caused by Antiplatelet medications include but not limited to
Hepatic disorder
Granulocytopenia
Thrombotic Thrombocytopenic Purpura</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AE) caused by Anti-platelet Medications</measure>
    <time_frame>2 years post index procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>AE caused by Antiplatelet medications include but not limited to
Hepatic disorder
Granulocytopenia
Thrombotic Thrombocytopenic Purpura</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AE) caused by Anti-platelet Medications</measure>
    <time_frame>3 years post index procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>AE caused by Antiplatelet medications include but not limited to
Hepatic disorder
Granulocytopenia
Thrombotic Thrombocytopenic Purpura</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AE) caused by Anti-platelet Medications</measure>
    <time_frame>4 years post index procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>AE caused by Antiplatelet medications include but not limited to
Hepatic disorder
Granulocytopenia
Thrombotic Thrombocytopenic Purpura</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AE) caused by Anti-platelet Medications</measure>
    <time_frame>5 years post index procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>AE caused by Antiplatelet medications include but not limited to
Hepatic disorder
Granulocytopenia
Thrombotic Thrombocytopenic Purpura</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Angina</condition>
  <condition>Chronic Coronary Occlusion</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Artery Stenosis</condition>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>Subjects receiving XIENCE Prime - Long Length (LL)</arm_group_label>
    <description>300 patients receive LL stent in 28, 33, or 38 mm length</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving XIENCE Prime - Core Length</arm_group_label>
    <description>200 patients receive Core Length stent in 8, 12, 15, 18 or 23 mm length</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Subjects receiving XIENCE Prime - Long Length (LL)</intervention_name>
    <description>Long Length</description>
    <arm_group_label>Subjects receiving XIENCE Prime - Long Length (LL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Subjects receiving XIENCE Prime - Core Length</intervention_name>
    <description>Core Length</description>
    <arm_group_label>Subjects receiving XIENCE Prime - Core Length</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Only patients in Japan, who are eligible to receive treatment for coronary arteries using
        the XIENCE PRIME Everolimus-Eluting Stent System are to be enrolled.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with ischemic heart disease who are eligible for treatment with XIENCE PRIME
             Everolimus Eluting Stent

          -  Patient provides Informed Consent Form

        Exclusion Criteria:

          -  If it is known at the time of index procedure that the patient is not able to return
             for the 8-month follow-up visit for angiogram and for the 1-year clinical follow-up,
             then the patient should not be registered in the PMS.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ken Kozuma, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Teikyo University Hospital, Toyko</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isao Tsuchii</last_name>
    <phone>81-3-4560-0980</phone>
    <email>isao.tsuchii@av.abbott.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Abbott Vascular Japan Co., Ltd.</name>
      <address>
        <city>Tokyo</city>
        <zip>108-6304</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isao Tsuchii, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 15, 2013</lastchanged_date>
  <firstreceived_date>September 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Angioplasty</keyword>
  <keyword>Drug eluting stents</keyword>
  <keyword>Stents</keyword>
  <keyword>Real world</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Coronary Occlusion</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
